Academia
The University of Oxford in the U.K., with the National Immunisation Schedule Evaluation Consortium, is planning a trial to evaluate the use of first and second doses of different COVID-19 vaccines.
A spirit of urgency and collaboration broke down traditional informational barriers as industry and academia organized like never before in modern history to develop a vaccine in just nine months.
Elevian believes that this single protein, a key player in the circulatory system, could be a game-changer in regenerative medicine.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A team led by Dr. Decio Eizirik, M.D., Ph.D., Scientific Director for Indiana Biosciences Research Institute Diabetes Center, has taken a step back from the traditional immune system study approach and found potential for treatment and, theoretically, even a cure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell, could have implications for gene editing therapies as well.
Pancreatic cancer is one of the deadliest forms of cancer. The five-year survival rate is a paltry 5-10%. The tumors are basically invisible to the immune system and rarely respond to chemotherapy or immunotherapy.
The nanoparticle vaccine development is going to be a great leap in vaccine technology. Here is everything you need to know about the upcoming technology.
PRESS RELEASES